Onco-Nephrology, which embodies the unique connection that exists for kidney disease and cancer in clinical medicine, continues to grow by leaps and bounds. The increasing interest in the subfield of Onco-Nephrology is witnessed by the recent conference dedicated to this area that took place in Philadelphia, Pennsylvania, USA. In this issue of the Journal of Onco-Nephrology, a series of papers addressing important topics in this area of subspecialization is presented as part of the Onco-Nephrology Highlights section. These papers are based on some of the lectures delivered at the above-noted Onco-Nephrology Symposium. I hope you find these four papers educational and practical in your provision of care to patients with cancer and kidney disease.
PerazellaMABernsJSRosnerMHCancer and the kidney: the growth of onco-nephrology. Adv Chronic Kidney Dis2014; 21(1): 4–6
2.
CosmaiLPortaCGallieniMPerazellaMAOnco-nephrology: a decalogue. Nephrol Dial Transplant2016; 31(4): 515–519
3.
Launay-VacherVPortaCCosmaiLIntroduction to the Journal of Onco-Nephrology. J Onco-nephrology2017; 1(1): 1–4
4.
GillSMausMVPorterDLChimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev2016; 30(3): 157–167
5.
FreyNVPorterDLCytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program)2016; 2016(1): 567–572
6.
FitzgeralsJCWeissSLMaudeSLet al.Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med201745e124.
7.
LeeDWBarrettDMMackallCet al.The future is now: Chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res2012; 18(10): 2780–2790
8.
MaudeSLFreyNShawPAet al.Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med2014; 371(16): 1507–1517
9.
BonifantCLJacksonHJBrentjensRJCurranKJToxicity and management in CAR T-cell therapy. Mol Ther Oncolytics2016316011.
10.
BrudnoJNKochenderferJNToxicities of chimeric antigen receptor T cells: recognition and management. Blood2016; 127(26): 3321–3330
11.
GruppSAKalosMBarrettDet al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med2013; 368(16): 1509–1518
12.
PerazellaMAMoeckelGWNephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol2010; 30(6): 570–581
13.
PerazellaMAOnco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol2012; 7(10): 1713–1721
de MiguelDGarcía-SuárezJMartínYGil-FernándezJJBurgaletaCSevere acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol Dial Transplant2008; 23(12): 3762–3766
17.
WallSMJohansenMJMolonyDADuBoseTDJrJaffeNMaddenTEffective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis1996; 28(6): 846–854
18.
WidemannBCSchwartzSJayaprakashNet al.Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy2014; 34(5): 427–439
GurevichFPerazellaMARenal effects of anti-angiogenesis therapy: update for the internist. Am J Med2009; 122(4): 322–328
21.
IzzedineHMangierMOryVet al.Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int2014; 85(2): 457–470
22.
ZhuXWuSDahutWLParikhCRRisks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis2007; 49(2): 186–193
CortazarFBMarroneKATroxellMLet al.Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int2016; 90(3): 638–647
29.
ShiraliACPerazellaMAGettingerSAssociation of acute interstitial nephritis with Programmed Cell Death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis2016; 68(2): 287–291
30.
BonifantCLJacksonHJBrentjensRJCurranKJToxicity and management in CAR T-cell therapy. Mol Ther Oncolytics2016316011.
31.
BrudnoJNKochenderferJNToxicities of chimeric antigen receptor T cells: recognition and management. Blood2016; 127(26): 3321–3330
32.
BridouxFLeungNHutchisonCAet al.International Kidney and Monoclonal Gammopathy Research Group. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int2015; 87(4): 698–711
33.
BonaudABenderSTouchardGet al.A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy. Blood2015; 126(6): 757–765
34.
PalladiniGHegenbartUMilaniPet al.A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood2014; 124(15): 2325–2332
35.
KourelisTVNasrSHDispenzieriAet al.Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol2016; 91(11): 1123–1128
36.
ZiogasDCKastritisETerposEet al.Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. Leuk Lymphoma2017; 58(8): 1832–1839
37.
HingoraniSRenal Complications of Hematopoietic-Cell Transplantation. N Engl J Med2016; 374(23): 2256–2267
38.
HingoraniSPaoESchochGGooleyTSchwartzGJEstimating GFR in adult patients with hematopoietic cell transplant: comparison of estimating equations with an iohexol reference standard. Clin J Am Soc Nephrol2015; 10(4): 601–610
39.
LaskinBLNehusEGoebelJFurthSDaviesSMJodeleSEstimated versus measured glomerular filtration rate in children before hematopoietic cell transplantation. Biol Blood Marrow Transplant2014; 20(12): 2056–2061
40.
LaskinBLGoebelJDaviesSMet al.Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant2011; 46(5): 682–689
41.
JodeleSDaviesSMLaneAet al.Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood2014; 124(4): 645–653
42.
JodeleSZhangKZouFet al.The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood2016; 127(8): 989–996
43.
SinghHKAndreoniKAMaddenVet al.Presence of urinary Haufen accurately predicts polyomavirus nephropathy. J Am Soc Nephrol2009; 20(2): 416–427
